Sarepta and REGENXBIO Settle AAV Patent Case

Company Sarepta Therapeutics / REGENXBIO Event Type Patent Litigation Settlement Modality AAV Gene Therapy Asset Elevidys (AAVrh74 Capsid IP) Target Not Applicable (Legal/IP Settlement) Disease Area Duchenne Muscular Dystrophy Summary REGENXBIO disclosed a 23 September settlement with Sarepta, the University of Pennsylvania and Catalent resolving…